PubMed Health⌕ Search

Biomedical subjects

A Rimpler

Publications and source records attributed to A Rimpler.

6 recordsLinked to original sources

Beta radiation exposure of medical staff and implications for extremity dose monitoring.

Sealed and unsealed beta radiation sources come into use to a greater extent in radiation therapy, e.g. for treating inflammatory joint diseases by radiosynoviorthesis (RSO), by injecting 90Y, 186Re or 169Er-solutions. Sealed 90Sr/90Y and 32P-sources or 188Re-liquid-filled balloon catheter are applied in vascular brachytherapy. Recently, 90Y-labelled antibodies are being successfully used in radioimmunotherapy (RIT) of malign lymphoma. Such practices require handling of high activities at small distances to the skin. Thus, the medical staff may be exposed to high beta doses. Investigations of the extremity exposure were performed at several workplaces, in particular during RSO treatments. The local skin dose (LSD), Hp(0,07), was measured with thin-layer TLD (LiF:Mg,P,Cu) fixed to the fingers (TLD-tapes). The findings indicate that the exposure of the staff can exceed the annual dose limit of 500 mSv when working at low protection standard. Routine monitoring of the extremity exposures with ring dosemeters appropriate to beta radiation and provided by the approved German dosimetry services was found to be needed. But even monitoring with these official 'beta-dosemeters' does mostly not give suitable results to demonstrate compliance with the dose limit. A study was conducted at RSO-workplaces in order reveal a correlation between doses measured with ring dosemeters and the maximum LSD obtained from the TLD-tapes. The results are discussed and conclusions for routine monitoring are drawn.

Beta Particles↗

[Radiation exposure in (90)Y-Zevalin therapy: results of a prospective multicentre trial].

UNLABELLED: AIM of this study was the assessment of the radiation exposure from preparation and application of (90)Y-Zevalin, the measurement of the dose rate at the patient, the exposure of family members as well as the determination of the activity concentration in urine of patients. METHODS: Overall data from 31 therapeutic administrations carried out in four institutions were evaluated. During preparation and application of (90)Y-Zevalin the finger exposures of radiochemists, technicians, and physicians were measured. The dose rate of the patient was measured immediately after radioimmunotherapy. In patients treated in a nuclear medicine therapy unit, urine was collected over a two day period and the corresponding activity was determined. Family members of outpatients were asked to wear a dosimeter over a seven day period. RESULTS: During the preparation we found a maximum skin dose of 6 mSv at the average, and during application of 3 mSv, respectively. After administration of (90)Y the dose rate was 0.4 +/- 0.1 microSv/h at 2 m distance. Urine measurements yielded a cumulated 24 h excretion of 3.9 +/- 1.4% and 4.4 +/- 1.4% within 48 h, respectively, that is equivalent to 43 +/- 18 and 50 +/- 20 MBq of (90)Y, respectively. Family members received a radiation exposure of 40 +/- 14 microSv over seven days. CONCLUSION: During preparation and application of (90)Y-Zevalin appropriate radiation shielding is necessary. For family members as well as nursing staff no additional special radiation protection measures beyond those being common for other nuclear medicine procedures are necessary.

Antibodies, Monoclonal↗

Comparison of measured and calculated dose rates for the Castor HAW 20/28 CG.

In January 2003 neutron and gamma dose rate measurements at a CASTOR HAW 20/28 CG were performed by the Bundesamt für Strahlenschutz at Gorleben. First, commercial dose rate measurement devices were used, then spectral measurements with a Bonner sphere system were made to verify the results. Axial and circumferential dose rate profiles were measured near the cask surface and spectral measurements were performed for some locations. A shielding analysis of the cask was performed with the MCNP Monte Carlo Code with ENDF/B-VI cross section libraries. The cask was modelled 'as built', i.e. with its real inventory, dimensions and material densities and with the same configuration and position as in the storage facility. The average C/E-ratios are 1.3 for neutron dose rates and 1.4 for gamma dose rates. Both the measured and calculated dose rates show the same qualitative trends in the axial and circumferential direction. The spectral measurements show a variation in the spectra across the cask surface. This correlates with the variation found in the C/E-ratios. At cask midheight good agreement between the Bonner sphere system and the commercial device (LB 6411) is found with a 7% lower derived H*(10) dose rate from the Bonner sphere system.

Computer-Aided Design↗

Applications.

Explore the source record for details and available documents.

Calibration↗